Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Elevation Oncology, Inc. Common stock

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. 
 
Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline.

K2 HealthVentures

Aisling Capital

Biotechnology Value Fund

BVF Partners

Vivo Capital

Janus Henderson Investors

venBio Partners

Cormorant Asset Management

Driehaus Capital Management

Samsara BioCapital

Qiming Venture Partners USA

Vertex Ventures HC

Elevation Oncology

Today we announced the appointment of Darcy Mootz, Ph.D., to our Board of Directors. 
 
Darcy Mootz, Ph.D., currently serves as President of Architect Therapeutics, a position she has held since April 2023. She is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations. 
 
https://lnkd.in/eztEX_eY
 
#Oncology #ADC #Innovation

In an interview with Bioprocess Online, Elevation Oncology’s CEO, Joseph Ferra, and CSO, Dr. David Dornan, shared their insights on what made EO-3021 worth licensing and how the company is executing its clinical strategy. 

Discover the factors that Elevation Oncology considered when licensing their lead ADC program, EO-3021, aimed at treating solid tumors that are likely to express Claudin 18.2.

Read the full interview by Tyler Menichiello on Bioprocess Online: https://bit.ly/3vVXK5w

#Oncology #ADC #Licensing #drugdevelopment

Senior writer Adam Feuerstein of STAT delves into Elevation Oncology's impressive market valuation surge in 2024, amidst a wave of investor interest in undervalued ADC companies. This comes as major players invest billions in ADC deals.

Discover more in Adam's insightful column (subscription required): https://bit.ly/4b9RHum

#oncology #valuation #drugdevelopment #marketvaluation

We had a wonderful and productive time at #JPM2024, meeting with other innovators in the healthcare industry to discuss what 2024 has in store and enjoying #SanFrancisco.

Great connecting and catching up with everyone! Until next year! 

#Oncology #ADC #Innovation #Biopharma

Elevation Oncology is excited to present a Trial in Progress poster for the currently enrolling Phase 1 study of EO-3021, a Claudin 18.2 ADC, today at the 2024 ASCO Gastrointestinal Cancers Symposium. 

https://lnkd.in/eJedHj-Q
 
$ELEV #ASCOGI2024 #clinicaltrial #claudin18 #ADC #drugdevelopment #cancer #oncology

Our CEO, Joseph Ferra, had a great conversation with host Matthew Pillar on Bioprocess Online’s Business of Biotech podcast, discussing our potential best-in-class #ADC candidate EO-3021 and the challenges of navigating today’s #biotech market.
 
Podcast website: https://lnkd.in/ekaGDDTV 
 
Listen on Apple podcasts: https://lnkd.in/eaderina
 
Listen on Spotify: https://lnkd.in/eaderina 
 
#Oncology #Innovation #Podcast

Today we announced program updates and upcoming #milestones including:
 
Plans to expand our clinical development program to evaluate EO-3021 in combination. We believe a combination approach has the potential to offer optimal outcomes to patients, particularly in the gastric cancer setting, with both immunotherapy and targeted agents. We expect to share details on our planned Phase 1 combination study in the first half of 2024.
 
HER3-ADC: Our second program is a differentiated HER3-targeting ADC. HER3 is a well-validated ADC target, which is overexpressed across solid tumors and often associated with poor outcomes. There are currently no HER3-targeted ADC agents approved for the treatment of cancer. We’re currently evaluating our HER3-ADC program and plan to nominate a development candidate in 2024.
 
https://lnkd.in/exKQWcXG 
 
#Oncology #Biotech #ADC #Innovation

Wishing a very happy and restful holiday season to our colleagues, partners and the patient communities we aim to serve. We are grateful for your contributions and collaboration. 

Looking forward to 2024!

#HappyHolidays #HappyNewYear #Oncology #Biotech

We had a great time at our in-person meeting in Austin, TX, in November. It was wonderful spending time with everyone, celebrating milestones, and meeting new team members.

We took this time to strategize internally through executive presentations and were excited to give back to the city of Austin by making gift bags for patients at the local children’s hospital.

Looking forward to a great 2024!

#GoTeam #GivingBack #Austin #Oncology #Biotech

November is #StomachCancerAwarenessMonth! Globally, stomach cancer is the fourth most common cancer and the second leading cause of worldwide cancer deaths. In the US alone, an estimated 26.5k new cases of stomach cancer will be diagnosed every year.
 
Learn more about stomach cancer awareness: https://lnkd.in/etQj25R4

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-5.88M -	-17.27M 193.52%	-32.04M 85.57%	-95.08M 196.76%	-45.70M 51.93%
depreciation and amortization		15K -	18K 20%	27K 50%	39K 44.44%
deferred income tax		5.14M -	-1.64M 131.87%		5.86M -
stock based compensation	13.50 -	52K 385,085.19%	1.57M 2,921.15%	3.21M 104.07%	3.33M 4.02%
change in working capital	423K -	4.90M 1,058.39%	283K 94.22%	6.29M 2,122.61%	-13.69M 317.65%
accounts receivables
inventory
accounts payables	460K -	5.22M 1,034.57%	-30K 100.57%	711K 2,470%	-5.86M 923.49%
other working capital	-37K -	-319K 762.16%	313K 198.12%	5.58M 1,682.43%	-7.83M 240.44%
other non cash items	8.99K -	-5.14M 57,263.52%	1.64M 131.87%	74K 95.48%	-6.01M 8,228.38%
net cash provided by operating activities	-5.45M -	-12.30M 125.65%	-30.17M 145.30%	-85.48M 183.37%	-56.18M 34.28%
investments in property plant and equipment		-71K -		-86K -
acquisitions net				44.31K -
purchases of investments				-112.31M -	-42.66M 62.02%
sales maturities of investments				68M -	54.20M 20.29%
other investing activites				-44.31K -
net cash used for investing activites		-71K -		-44.40M -	11.54M 126.00%
debt repayment				-470K -
common stock issued	7.19M -	20K 99.72%	97.06M 485,210.00%	19K 99.98%	48.00M 252,526.32%
common stock repurchased				-35K -	-24K 31.43%
dividends paid
other financing activites	10.79K -	90.01M 834,475.80%	-11K 100.01%	30M 272,827.27%
net cash used provided by financing activities	7.19M -	90.03M 1,152.14%	97.05M 7.80%	29.51M 69.59%	47.98M 62.55%
effect of forex changes on cash
net change in cash	1.74M -	77.66M 4,363.22%	66.88M 13.88%	-100.37M 250.06%	3.34M 103.33%
cash at beginning of period		1.74M -	79.40M 4,463.22%	146.28M 84.24%	45.92M 68.61%
cash at end of period	1.74M -	79.40M 4,463.22%	146.28M 84.24%	45.92M 68.61%	49.26M 7.27%
operating cash flow	-5.45M -	-12.30M 125.65%	-30.17M 145.30%	-85.48M 183.37%	-56.18M 34.28%
capital expenditure		-71K -		-86K -
free cash flow	-5.45M -	-12.37M 126.95%	-30.17M 143.89%	-85.57M 183.65%	-56.18M 34.35%

COM:ELEVATIONONCOLOGY

Elevation Oncology, Inc.

Last Close

0.61

22/11 21:00

Market Cap

34.29M

Beta: -

Volume Today

188.17K

Avg: -

Preview